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A placebo-controlled study was employed to evaluate the
effectsof oral amrinone in patients with congestiveheart
failure. After a baseline period of at least 4 weeks of
standard treatment for refractory congestive heart fail-
ure, oral amrinone was added to the treatment regimen
of 173patients. Patients were predominantly male (89%),
aged 24 to 76 years (mean 54), with ischemic (52%) or
idiopathic (37%) dilated cardiomyopathy, in New York
Heart Association functional class II (40%), III (59%)
and IV (l %) and having a mean (± standard deviation)
left ventricular ejection fraction of 25 ± 15%.
Phase 1: After the addition of amrinone (113 ± 33
mg three times daily), 52 patients (30%) showed a max-
imal increase in treadmill exercise time exceeding2 min-
utes (Naughton protocol), 72 (42%) had a lesser increase,
24 (14%) developed limiting adverse reactions, 20 (12%)
died and 5 dropped out of the study. Fifty-two "re-
sponders" (30%) who were free of limiting side effects
and had a greater than 2 minute increase in exercise
time were randomized in double-blind fashion to con-
tinued amrinone or switched to placebo (each plus stan-
dard treatment) for an additional 12 weeks.
Phase 2: Comparison of 31 of these 52 responders
who continued to receive amrinone with the remaining
Introduction
Treatment of myocardial failure that either improves the
contractile state of the myocardium (1,2) or reduces imped-
ance to left ventricular ejection (3,4) increase s the cardiac
output and reduces ventricular filling pressures. Both acutely
*A listing of the Amrinone Multicenter Study Investigators appears at
the end of the text.
This study was supported in part by grants from the Veterans Admin-
istration, Washington, D.C. and a research grant from Sterling-Winthrop
Research Institute, Rensselaer, New York. Manuscript received January
3. 1984; revised manuscript received April 23. 1984. accepted May 1.
1984.
Address for reprints: Robert Dillianco. MD. Cardiology Section (l51O).
Veterans Administration Medical Center . 50 Irving Street N.W .. Wash-
ington. D.C . 20422.
© 1984 by the American College of Cardiology
21 randomized to placebo revealed no significant differ-
ences in vital signs, indexes of left ventricular size and
function, systolic time intervals or maximal exercise time.
Continued follow-up study of patients receiving either
amrinone or placebo revealed decreases in exercise times
of 7 and 10%, respectively (both p < 0.05 compared
with before randomization). Episodes of worsened
congestive heart failure severe enough to mandate ter-
mination of double-blind treatment were as frequent in
patients taking placebo (4 [18%] of 21) as in those taking
amrinone (4 [13%] of 31; p = NS). The average symp-
tom score and functional class of each treatment group
remained comparable. Adverse effects such as gastroin-
testinal and central nervous systemcomplaints were more
common with amrinone treatment as were elevations of
serum liver enzymes and reduced platelet counts.
This large multicenter, randomized double-blind
withdrawal study revealed no change in estimates of
cardiac performance after the discontinuation of amri-
none. These findings suggest that amrinone, in the dos-
ages tested, does not importantly improve cardiac func-
tion beyond that provided by standard treatment with
digoxin, diuretic drugs and vasodilators.
(1-5) and chronically (6,7), these actions reduce some of
the unfavorable effects of heart failure . At present, cardiac
glycosides are the only available positive inotropic agent s
for the long-term oral treatment of heart failure. Digitali s
exerts demon strable, though modest, positive inotropic ac-
tions that are of controversial clinical benefit , especially in
patients with chronic congestive heart failure and sinus rhythm
(8,9).
Amrinone (Fig. I) is a recently discovered bipyridine
derivative shown to have positive inotropic and vasodilator
activity in in vitro (10- 12), in vivo (11,13-15) and in clin-
ical studies (16-32) through as yet undetermined mecha-
nisms. It is effective orally or parenterally (23), and the
improvement in hemodynamics of patients with congestive
0735-1097/84/$3.00
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F = female; LVEF = left ventricular ejection fraction determined by
radionuclide multiple gated acquisition scanning; M = male; NYHA
class = New York Heart Association functional class.
Study design (Fig. 2). The protocol consisted of an
initial baseline period of at least 4 weeks, termed phase 0,
during which patients received constant dosages of conven-
tional medications for congestive heart failure including car-
diac glycosides, diuretic drugs and vasodilators (Table I).
Patients were required to have a stable clinical course during
this phase. Sequential clinical evaluations included electro-
cardiographic and echocardiographic studies, systolic time
interval determinations, maximal graded treadmill exercise
tests and blood chemistry and hematologic profiles.
Phase 1. Oral amrinone was introduced in single-blind
uncontrolled fashion in doses of 100 mg three times daily
in all patients. Clinical evaluations (as just described) in-
cluding an interim history were performed on multiple oc-
casions during and at the end of this phase. Dosage reduc-
tions were accomplished in patients with presumed drug-
related adverse reactions and dosages advanced for an in-
adequate clinical response. Arnrinone dosages ranged from
75 to 200 mg three times daily. The phase was terminated
when an improvement in clinical course and exercise ca-
pacity was present for at least 4 weeks without a change in
the dosages of standard medications and amrinone. Data
from patients showing toxicity or inadequate clinical im-
provement during phase 1 at the dosages tested were not
analyzed further except with regard to adverse effects. Those
patients showing an improvement in exercise time of more
than 2 minutes and who were free of limiting side effects,
whom we categorized as "responders" to amrinone, formed
the study group and were allowed to continue into the dou-
ble-blind withdrawal phase.
Phase 2. The double-blind randomization of patients to
continued use of amrinone at the dosage found effective
during dose titration or to placebo occurred in phase 2.
Randomization was accomplished through the sequential use
of randomized prepackaged pharmaceutical supplies (Ster-
ling-Winthrop Research Institute). Patients were evaluated
Figure 1. Amrinone structural formula.
heart failure resulting from parenterally administered am-
rinone is quantitatively similar to that of dobutamine and
possibly is sustained longer (:24). Little is known regarding
the long-term efficacy and safety of treatment with amrinone
(21,22) and no large-scale randomized double-blind and
placebo-controlled trials have been reported. Potentially
limiting adverse effects reported in small studies
(17-20,24,25,28,30-32) during extended dosage have in-
cluded gastrointestinal disturbances, abnormal serum liver
enzyme levels, thrombocytopenia, arrhythmia, fever and
viral-like illnesses.
Accordingly, we performed a multicenter randomized
double-blind and placebo-controlled withdrawal study in
which each patient was initially treated with arnrinone for
the purpose of identifying a group that both tolerated and
was favorably affected by treatment. We then compared the
continuation of amrinone for up to 12 weeks with the re-
introduction of placebo in this responding group of patients
(33).
Methods
Patient sample (Table 1). Of the 176 patients who were
initially entered, the study group comprised only 173 pa-
tients since 3 did not satisfy the entry criteria. Inclusion
criteria were: 1) congestive heart failure for at least 6 months;
2) written consent approved by the respective institutional
review board; 3) symptom-limited exercise capacity ranging
from 8 to 12 minutes (with rare exceptions) on treadmill
testing according to a modified Naughton protocol; 4) ex-
ercise durations on at least two sequential tests that agreed
within 20% of the results of the baseline test; 5) left ven-
tricular ejection fraction not greater than 44%; and 6) car-
diomegaly or increased pulmonary vascularity, or both, on
chest X-ray examination. Exclusioncriteria were: I) platelet
counts of 150,OOO/mm3 or less on two occasions; 2) unstable
angina or angina that limited exercise capacity; 3) myo-
cardial infarction within the past 3 months; 4) heart failure
resulting from uncontrolled hypertension or obstructive val-
vular, hypertrophic, restrictive or pericardial heart disease;
5) severe liver or renal impairment; 6) a requirement for
disopyramide treatment of arrhythmia; or 7) evidence of
sustained or life-threatening ventricular arrhythmia within
1 month.
Table 1. Patient Sample
No. of patients
Mean age
Etiology of heart failure
NYHA class
LVEF
Medications
173 (154 M, 19 F)
55 years (range 24 to 76)
89 (51%) ischemic heart disease
79 (45%) history of myocardial infarction
26 (15%) history of coronary bypass surgery
64 (37%) idiopathic heart disease
9 (5%) valvular heart disease
II (6%) hypertensive heart disease
2.6 ± 0.5 (67 patients class II; 103
patients class III; 3 patients class IV)
25 ± 15%
89% digoxin
89% diuretic drug
62% vasodilator
JACC Vol. 4, No.5
November 1984:855-66
DIBIANCO ET AL.
ORAL AMRINONE FOR CONGESTIVE HEART FAILURE
857
Time ·3 mos. ·2 mos. ·1 mos. o 1 mos. 2 mos. 3 mos.
Placebo
Amrinone
150mg ~-------------,
----------i--------------'
----------------·i
Dose ~
r--:-----' 1'"-----------.....,Baseline Titration (TID)
Figure 2. Amrinone study design. TID = three
times daily.
Phases: Phase 0 Phase 1 Phase 2
Control: Uncontrolled Placebo·Controlled
Blinding: Single·Blind Double·Bllnd
at 2 week intervals for 12 weeks unless they dropped out
of the study because of worsened congestive heart failure
or adverse effects. All tests were repeated at the termination
of the phase and, if possible, before the patient dropped out
of the study.
Exercise protocol. Maximal graded treadmill exercise
testing was performed according to a modified Naughton
protocol using 2 minute stages (1 mile/hlO% grade, 1.5/0,
2.0/3.5,2.017,2.0110.5,3.017.5,3.0/10.0,3.0112.5,3.0115.0
and 3.4/14.0). Patients were exercised to an end point of
severe fatigue or dyspnea. Cuff blood pressure measure-
ments were made during the last 30 seconds of each stage
of exercise, at peak exercise and at 2 minute intervals after
exercise. A 12 lead electrocardiogram was recorded before
exercise, at peak exercise and during the recovery period,
and one or more electrocardiographic leads were continu-
ously monitored during testing.
Echocardiographic studies. M-mode echocardiograms
were recorded at paper speeds greater than 25 mm/s with
the patient in the supine or modified left lateral decubitus
position. Attempts were made to determine the maximal
baseline diameters of the left ventricle at end-systole and
end-diastole and to obtain adequate endocardial echoes from
similar transducer positions.
Systolic time intervals. These measurements were ob-
tained manually or by computer-assisted methods from
simultaneous high speed recordings (~ 100 mm/s) of the
electrocardiogram, a phonocardiogram and an indirect ca-
rotid pulse tracing.
Symptom scores. Symptom scores were obtained from
patient diaries that were completed for each week in the
study. Patients were requested to rate the following four
symptoms: orthopnea, dyspnea, edema and fatigue accord-
ing to five degrees of severity including "very bad" (as-
signed a value of 2.5 points), "bad" (2.0 points), "mod-
erately severe" (1.5 points), "slight" (1.0 points) and "no
problem" (0 points). A score of 10 points obtained by
registering' 'very bad" for each of the symptoms listed was
the highest and most symptomatic score possible; a score
of 0 was the best and could only be obtained if the patient
estimated each of the four symptoms as "no problem."
Symptom scores were analyzed for the last 2 to 4 weeks of
each phase of study.
Functional class. The New York Heart Association
functional classification was determined according to the
definitions given (34,35).
Laboratory profile. A complete laboratory profile in-
cluding a complete blood count, platelet count, urinalysis
and determination of blood sugar and urea nitrogen, cre-
atinine, creatine kinase, serum glutamic oxaloacetic and
pyruvic transaminases, bilirubin, alkaline phosphatase, lac-
tic dehydrogenase, uric acid, cholesterol, triglycerides, total
protein, albumin and serum sodium, potassium, chloride,
bicarbonate, calcium and phosphorous was obtained before
entry into the study and at the end of each phase. Abbre-
viated laboratory profiles were obtained at each 2 week visit.
Statistical analysis. The data were derived from all pa-
tients studied in the 15 medical centers enumerated. Inter-
investigator comparisons of patient groups for demographic
variables, response variables and conventional medication
usage were made. Descriptive and measured variables were
compared during the baseline (phase 0), dose titration (phase
1) and withdrawal (phase 2) phases of study. A paired t test
(two-tailed) was used to evaluate the single-blind addition
of amrinone to conventional treatment, and groups were
compared for demographic descriptors as absolute and per-
cent changes in response variables using the unpaired t test.
Diuretic drug dosages of 50 mg of hydrochlorothiazide and
40 mg of furosemide were considered equivalent for statis-
tical purposes. Validity of randomization to amrinone-con-
tinued and placebo-substituted groups was confirmed with
respect to demographic and response variables at baseline
and before the withdrawal phase. The percent change from
baseline (see Table 4) and from the end of the dose titration
phase (see Table 5) to the end of the withdrawal phase was
compared for amrinone and placebo groups in an unpaired
and paired manner. A comparison of the number of patients
terminating phase 2 because of worsened congestive heart
failure and adverse reactions with regard to treatment was
made using the chi-square analysis for nonparametric data.
The chi-square analysis was also used to determine the sta-
tistical significance of changes in functional class at different
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Table 2. Results of Initial Treatment With Amrinone (phase 1)*
Baseline Amrinone p Value
No. of patients 173 173
Symptom score] 5.8 ± 1.4 5.3 ± 1.6 NS
NYHA class 2.6 ± 0.5 2.6 ± 0.6 NS
Body weight (kg) 76.8 ± 12 76.4 ± 12 NS
Rest heart rate (beats/min) 85 ± 14 89 ± 17 <0.01
Rest systolic BP (mm Hg) 117 ± 18 117 ± 20 NS
Digoxin dosage (mg) 0.23 ± 0.06 0.23 ± 0.07 NS
Furosemide dosage (mg) 99 :t 71 106 :t 90 NS
LV internal size (end-diastole)(cm) 7.0 :t 1.0 6.9:t 1.1 NS
Shortening fraction (%) 17.2 ± 7.1 17.8 ± 8.7 NS
PEP (seconds) 0.15 ± 0.04 0.14 ± 0.04 NS
LVET (seconds) 0.30 ± 0.07 0.29 ± 0.07 NS
QSl (seconds) 0.44 ± 0.10 0.43 ± 0.10 NS
Exercise capacity (seconds) 601 ± 141 678 ± 211 <0.001
VOl (ml/kg) 15.8 ± 3.7 16.4 ± 4.5 NS
rxcc VoL 4, No,S
November 1984:855-66
*Mean values (± SO) are shown for indicated variables for patients at baseline (left column) and after 4
weeks or more of amrinone (right column); tsymptom score represents an average rating by the patient for
symptoms of breathlessness during the day and at night, edema and fatigue. An average rating number is given
to symptoms (see Methods). BP = blood pressure; LV = left ventricle; LVET = left ventricular ejection
time; PEP = preejection period; QS2 = interval from onset of the Q wave to the onset of the second heart
sound; VOl = maximal oxygen consumption attained with exercise, measured directly; other abbreviations as
in Table I.
phases of study. The minimal level of acceptable signifi-
cance was a probability (p) value of less than 0.05. All
values are expressed as the mean ± standard deviation
unless otherwise indicated.
Results
Phase 0: baseline exercise comparisons. Exercise test-
ing in the month preceding amrinone treatment demon-
strated an insignificant change in exercise times between
sequential tests (584 ± 135 versus 601 ± 141 seconds).
Phase 1: single-blind dose titration with amri-
none. The responses after 4 weeks or longer of an amri-
none-supplemented regimen are summarized in Table 2. A
significant but slight increase in heart rate at rest and a
modest (12%) increase in exercise time occurred after am-
rinone for the entire group. Fifty-two patients (30%) re-
sponded to amrinone with a 2 minute or greater increment
in exercise time before the appearance of limiting side ef-
fects. In 72 patients (42%), the increment in exercise time
was less than 2 minutes. Twenty-four patients (14%) were
excluded because of important adverse reactions that pre-
cluded the continuation of treatment, 20 patients (12%) died
and 5 patients dropped out for reasons unrelated to the study.
The clinical characteristics of the group showing an ini-
tial benefit to amrinone were similar to those of the other
groups with respect to demographic and response variables
(Table 3). Responders to amrinone could not be predicted
on the basis of any variable of cardiac performance assessed,
although responders tended to have idiopathic cardio-
myopathy and a longer left ventricular ejection time more
frequently than did nonresponders. A trend toward more
severe degrees of cardiac impairment was evident in the
group of patients who died during this phase. (This group
has a higher functional class and heart rate at rest and a
reduced left ventricular ejection fraction and time, exercise
time and QS2interval.) The percent change after the addition
of amrinone for the individual variables is shown in Table
4 for all groups of patients. The reductions in functional
classification and increases in exercise capacity of the group
that responded reflect the method of classifying patients.
The percent of patients in functional classes II (40%), III
(59%) and IV (1%) did not change significantly after am-
rinone. The dissociation of symptom scores reported in the
diaries with functional class and exercise capacity is noted.
The minor changes seen in other variables are of borderline
statistical significance and not clinically meaningful.
Phase 2: double-blind withdrawal of amrinone.
Twenty-one patients underwent randomization to placebo
substitution and 31 patients continued taking amrinone. There
were 18 patients in functional class II and 34 in classes III
lACC Vol. 4, No.5
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Table 3. Demographic and Clinical Response Variables at Entry Into the Study (baseline)*
Adverse Patients
Responders Reactors Who Died Nonresponders
No. of patients 52 24 19 78
Etiology of heart failure
Ischemic heart disease 18 14 II 46
History of MI 17 11 9 42
History ofCABG 7 4 2 13
Idiopathic heart disease 25 8 7 24
Valvular heart disease 4 I I 3
Hypertension 5 I 0 5
LVEF (%) 26 ± 15 27 ± 16 IS ± II 26 ± 14
Digoxin dosage (mg) 0.22 ± 0.06 0.26 ± 0.05 0.21 ± 0.07 0.23 ± 0.07
Furosemide dosage (mg) 91 ± 58 112 ± 87 114 ± 56 95 ± 76
Symptom score 5.6 5.8 6.9 5.9
NYHA class 2.7 2.5 3.0 2.6
Body weight (kg) 76.5 81.6 72.7 76.3
Rest heart rate (beats/min) 80.8 85.2 94.9 84.3
Rest systolic BP (mm Hg) 118 119 109 119
LV internal size (end-diastole) (em) 6.8 7.0 7.2 6.9
Shortening fraction (%) 18.5 17.6 15.2 17.1
PEP (seconds) 0.15 0.15 0.13 0.14
LVET (seconds) 0.33 0.27 0.27 0.29
QS2 (seconds) 0.48 0.41 0.40 0.43
Exercise capacity (seconds) 619 573 524 616
V02(mllkg) 17.3 15.0 15.5 15.8
p Value
o.oir
0.003t
0.003*
0.02§
0.0311
*Patients categorized according to the subsequent response to amrinone in phase 1 (favorable responders, patients with limiting adverse reactions,
those who died and nonresponders); tp value for group that died compared with all other groups; *p value for responders compared with another groups;
§p value for responders compared with group that died only; lip value for both responders and nonresponders compared with group that died only; CABG
= coronary artery bypass graft; MI = myocardial infarction; other abbreviations as before.
and IV, No significant differences were observed after the
introduction of placebo with respect to symptoms, physical
findings, medication requirements (especially diuretic drugs),
left ventricular dimensions and ejection phase indexes by
echocardiography (including mean velocity of circumfer-
ential fiber shortening, which is not shown) and systolic
time intervals for the overall group (Table 5).
Exercise capacity was observed to decrease modestly in
both amrinone- and placebo-treated patients ( - 7 and - 10%
respectively; both p < 0.05 compared with values at entry
into this phase). Patients in functional classes III and IV
observed to be responders to amrinone during phase I of
the study tended to have a greater reduction in the mean
exercise time during phase II with placebo treatment ( - 82
seconds) than with continued amrinone ( -18 seconds; p =
NS) (Table 6). The largest increases in exercise times during
phase 2 occurred in patients in functional class III, regardless
of their initial response to amrinone. The mean exercise
improvement while taking amrinone for the 50 patients in
functional class III (regardless of initial exercise response
to amrinone) was 70 seconds compared with placebo; this
was marginally significant (p < 0.0545)(Table 6). No de-
terioration of symptoms, left ventricular size or function or
change in the frequency of episodes of worsened congestive
heart failure occurred after the reintroduction of placebo
treatment compared with amrinone.
Adverse effects (Tables 7 and 8). Adverse effects that
occurred during phase 1 of the study were each considered
to be amrinone-related since a comparable control group
was not studied (Table 7). Minor adverse effects were more
common at higher dosages, and only occasionally did dos-
age adjustment result in the complete disappearance of ad-
verse effects. Complaints of abdominal discomfort were
somewhat reduced when amrinone was ingested after meals
or with antacids. Diarrhea sometimes responded to the con-
comitant use of a bulk laxative or increased intake of dietary
fiber. During the double-blind comparison with placebo,
gastrointestinal and central nervous disturbances were sig-
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Table 4. Percent Change From Baseline for Groups Shown After the Addition of Amrinone in Phase I of Study
Adverse
Responders Reactors Died Nonresponders
No, of patients 52 24 19 78
Symptom score -8,7 -0.9 0.1 -3,5
NYHA class -10,7 11,8 8,3 0,2
Body weight (kg) 0,1 -0.5 -0.8 - 1.0
Rest heart rate (beats/min) 3.5 10,8 3,2 7.4
Rest systolic BP (mm Hg) 2.3 1.1 -7.4 0.9
LV internal size (end-diastole) (em) -0.1 0.8 -0.30 - 1.8
Shortening fraction (%) 9.9 26,6 4.0 4.5
Digoxin dosage (mg) 5.0 0.0 -5.0 0.0
Furosemide dosage (mg) 0.0 -5,0 46 5,0
PEP (seconds) -1.1 -16.1 8.4 2.1
LVET (seconds) -2.5 0.4 -6.6 -1.8
QS2 (seconds) -0.5 -1.1 -2.5 -4.4
Exercise capacity (seconds) 38.8 8.8 - 1.0 1.1
V02 (mllkg) 8,9 17.4 -12.0 6,8
p Value
O.OOOI*t
0.02:1:
O.OU
0.05§
NA
*p value for responders compared with all other groups; tp value for nonresponders compared with group with adverse reactions only; :l:p value for
group that died compared with all other groups; §p value for adverse reactors compared with all other groups; NA = not applicable; other abbreviations
as before,
nificantly more common in patients taking amrinone; this
finding was unchanged when all patients entering phase 2
were considered (Table 8), Suspected upper respiratory in-
fections were more frequently reported by patients taking
amrinone, while episodes of modestly increased heart failure
(observed at interim visits) were more frequent in patients
receiving placebo,
During the single-blind introduction of amrinone (phase
I), significant increases occurred in the mean levels of serum
lactic dehydrogenase and glutamic oxaloacetic transami-
Table 5. Percent Change in Response Variables Observed in the Withdrawal Phase (phase 2) for Amrinone-Supplemented and
Placebo-Substituted Groups Compared With the Final Evaluation in Phase I
Amrinone p Value* Placebo p Value* A vs. P p Value*
No, of patients 31 21
Symptom score 21.4 <0.05 8.4 NS NS
NYHA class 5,9 NS 7.9 NS NS
LVEF -3.3 NS 8,3 NS NS
Body weight (kg) 0.2 NS 0.7 NS NS
Rest heart rate (beats/min) 3.6 NS -6.2 NS NS
Rest systolic BP (mm Hg) 0.5 NS -3.2 NS NS
LV internal size (end-diastole) (em) 3,1 NS 0.7 NS NS
Shortening fraction (%) -5.1 NS 14.2 NS NS
Digoxin dosage (mg) 0.0 NS 5.0 NS NS
Furosemide dosage (mg) -4,0 NS 6.0 NS NS
PEP (seconds) 2,5 NS -2.6 NS NS
LVET (seconds) 3.4 NS 0.6 NS NS
QS2 (seconds) 2,7 NS 3,7 NS NS
Exercise capacity (seconds) -6.7 <0,05 - 9,8 <0.05 NS
V02 (mllkg) -3.7 NS -0,6 NS NS
*p values are compared with the values obtained just before withdrawal (that is, at the end of the dose titration phase); A vs. P p value refers to the
comparison between the percent change in those taking arnrinone and the percent change in those taking placebo. Abbreviations as before,
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Table 6. Summary of Exercise Test Results Categorized According to Functional Classification
and Initial Response to Amrinone Treatment*
Baseline Phase I Phase 2
Class n Mean Mean Change Treatment n Mean Change
Phase I: Increment in Exercise Time (seconds) of Less Than 2 Minutes ("nonresponders")
II 26 664 697 33 Amrinone 11 661 -11
II Placebo 15 721 6
III 21 616 635 19 Amrinone 10 677 85
III Placebo 11 676 2
Phase 1: Increment in Exercise Time of at Least 2 Minutes ("responders")
II 17 724 966 242 Arnrinone 12 833 -122
II Placebo 5 909 -82
III 29 567 776 209 Arnrinone 16 754 -18
III Placebo 13 698 -82
*Patients are categorized on the basis of the initial introduction of arnrinone into nonresponders and re-
sponders (phase 1). Patient numbers reflect paired data. The subsets of patients classified according to New
York Heart Association functional classification on entry into the study and their subsequent treatments in the
withdrawal phase (phase 2) of the study are shown. Note the mean changes in exercise times for the groups
and that the largest changes in exercise time occurred in class III patients, regardless of their initial exercise
response to amrinone (see text).
nase, whereas platelet counts decreased by approximately
17% (Table 7). In phase 2, laboratory findings were similar
except for slightly reduced platelet counts in patients taking
amrinone. Worsening of heart failure in this responding
group was not increased during the withdrawal of amrinone.
Discussion
Acute versus chronic studies of treatment of heart
failure. Many investigations into the treatment of heart fail-
ure, including those concerning pharmacologic agents, have
evaluated changes after acute interventions and extrapolated
these findings to chronic heart failure. Other studies
(2,5,9,35-38) have cautioned against such extrapolations
because there may be major differences between the acute
and chronic response, Little emphasis has been given to the
magnitude of observed changes and the extent to which these
changes are clinically meaningful in long-term follow-up
(35,37).Short-term or acute intervention studies (37) largely
neglect the variabilities in both subjective and objective
longitudinal patient responses that must be considered in
order to prove long-term effects. Acute studies are able to
measure small changes that deviate from closely monitored
and stable baselines, thus avoiding confounding training
effects, possible drug tolerances, drug interactions or ad-
verse effects that may appear only after long-term dosing.
They further avoid alterations of diet, compliance and auto-
nomic adjustments that are inherent in patients studied lon-
gitudinally. Acute studies are important research tools for
registering drug-related changes, but may not reflect changes
found during long-term drug administration. Chronic studies
must overcome many more obstacles to demonstrate une-
quivocal clinical benefit or detriment from a specific treat-
ment. For this reason, the benefits of digitalis, hydralazine,
prazosin and nitrates, which have favorable short-term drug-
related effects, remain controversial during the long-term
treatment of congestive heart failure (8,9,35,37-39).
Effects of amrinone on chronic heart failure. In the
present study, we evaluated amrinone in patients with chronic
heart failure for periods of 4 months. The study benefited
from a large patient experience, extensive clinical profiling
of subjective and objective variables, prospective study de-
sign and the double-blinding of amrinone withdrawal. It
showed that the withdrawal of amrinone did not produce
significant deterioration of symptoms, left ventricular size
or function or exercise tolerance. Investigators did record
more frequent episodes of increased heart failure in the
follow-up of patients withdrawn from amrinone compared
with those continued on treatment; these episodes, however,
were not severe enough to preclude continuation in the study.
Severe episodes of heart failure occurred with equal fre-
quency in patients receiving amrinone and placebo. Amri-
none-treated patients showed more frequent gastrointestinal
and central nervous system side effects and a lower mean
platelet count than those taking placebo.
A number of hypotheses may expLain the Lack of deteri-
oration in exercise capacity on withdrawaL of amrinone.
Among the possibilities are that an altered congestive heart
failure state resulted from initial drug treatment, the long-
term drug effect was reduced in magnitude, the placebo
withdrawal period was too short to separate groups, the use
of a variable (for example, exercise time) was not a sensitive
indicator of changes in the heart failure state or the drug
was ineffective and the initial changes resulted from a pla-
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Table 7. Adverse Effects Observed During the Uncontrolled Addition of Amrinone to
Conventional Treatment During the Dose Titration Phase of Study (Phase I)
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Gastrointestinal disturbances
Nausea
Anorexia
Abdominal pain
Diarrhea
eNS complaints
Dizziness
Headache
Lightheadedness
Somnolence
Fatigue
Increased heart failure
Upper respiratory infection
Death
Thrombocytopenia
Arrhythmia*
Probable ischemic episode
Hepatic dysfunction
Fever
Viral-like illness
Laboratory abnormalitiestj
Platelets
SGOT
SGPT
LDH
Alk Phos
Bilirubin
Total
n
69
46
17
17
22
29
3
10
4
5
27
27
22
18
17
16
12
12
10
7
(25/172)
(91168)
(10/103)
(1/165)
(01168)
(01113)
173
%
(39)
(27)
(10)
(10)
(13)
(17)
(2)
(6)
(2)
(3)
(15)
(15)
(13)
(10)
(10)
(9)
(7)
(7)
(6)
(4)
-46.3 ± 83.7
17 ± 24
29 ± 176
22 ± 75
3 ± 34
-0.04 ± 0.4
p Value
<0.001
0.02
NS
<0.001
NS
NS
*No prospective and systematic survey was made of the prevalence, type or severity of atrial or ventricular
arrhythmia. Only observations considered important by the investigators are recorded. t Absolute change in
values from end of phase I minus last value measured before amrinone in phase 0 (baseline). tFractions in
parentheses represent number of patiehts with greater than three times the upper limit of normal range divided
by number of patients having test performed. In the case of platelets, the numerator represents patients with
under 100,000 platelets/mm'. Alk Phos = alkaline phosphatase; eNS = central nervous system; LDH =
lactic dehydrogenase; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvic
transaminase.
cebo or training effect. Similar problems stemming in part
from the design of the withdrawal phase have recently been
discussed for digoxin (9).
Comments on the study design. The present study de-
sign involves the single-blind (that is, uncontrolled) dose
titration of all patients who are in apparently stable condition
during a short baseline period, followed by the randomized
double-blind and placebo-controlled withdrawal in a se-
lected group of patients. Selected patients are required to
demonstrate a favorable initial response to active drug treat-
ment and be free of limiting side effects. Each of these
phases requires further comment.
Critique of the initial single-blind treatment phase. In
the initial phase of this study, all patients were treated with
active drug. Compared with a parallel designed placebo-
controlled study in which only half of the patient group
receives treatment, this design maximizes patient exposure
to active treatment and uncovers more data regarding ad-
verse drug reactions (40), It further provides a large patient
sample for dosage titration and may offer a more complete
review of optimal dose relative to the incidence and type
of adverse reactions. A major drawback of this design,
however, is the lack of a parallel control group, which
compromises all conclusions drawn from the single-blind
administration of drug during titration. This study phase
yields only estimates of drug-related side effects and ben-
efits. Effects observed may not be solely attributed to drug
since spontaneous events or changes related to study are
unknown. Because spontaneous adverse events cannot be
estimated, they must be added to the adverse effects assigned
to active drug. Benefits stemming from participation in a
study must similarly be attributed to possible drug effect.
It may be argued that the uncontrolled phase of study serves
primarily to identify patients tolerant to and favorably af-
fected by initial treatment (40).
Critique of the double-blind withdrawal phase. A draw-
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Table 8. Adverse Effects Observed During the Controlled Withdrawal of Amrinone in Phase 2
of the Study
Gastrointestinal disturbances
Nausea
Anorexia
Abdominal pain
Diarrhea
Vomiting
eNS complaints
Dizziness
Headache
Lightheadedness
Paresthesia
Fatigue
Increased heart failure
Upper respiratory infection
Death
Thrombocytopenia
Arrhythmia
Probable ischemic episode
Hepatic dysfunction
Fever
Viral-like illness
Laboratory abnormalities
Platelets
SGOT
SGPT
LDH
Alk Phos
Bilirubin
Amrinone
(n = 55)
15 (27%)
II
4
3
5
I
II (20%)
o
4
3
2
9 (16%)
9 (16%)
12 (22%)
1(2%)
2 (4%)
8 (15%)
4 (7%)
5 (9%)
3 (6%)
1(2%)
(3/52) 215 ± 77
(2/52) 36 ± 32
(3127) 45 ± 38
(1/52) 222 ± 87
(0/52) 48 ± 24
(0/32) 0.7±0.3
Placebo
(n = 52)
4 (8%)
o
I
2
I
o
2 (4%)
1
1
2
o
8 (15%)
17 (33%)
4 (8%)
0(0%)
o (0%)
4 (8%)
7 (14%)
2 (4%)
2 (4%)
0(0%)
(1/47) 264± 100
(2/48) 49 ± 29
(2/21) 32±22
(0/47) 203±78
(0/48) 55 ± 33
(0/22) 0.8±0.7
p Value
0.01
0.01
NS
0.05
0.04
NS
NS
NS
NS
NS
NS
NS
0.008
NS
NS
NS
NS
NS
Note that the number of patients includes all patients who were followed up in phase 2 of the study regardless
of exercise performance in phase I. Abbreviations and format as in Table 7.
back of the withdrawal design is patient selection. To be
randomized, each patient must show a predetermined fa-
vorable response to drug without limiting adverse effects.
So-called sequence effects of prior therapy may alter the
underlying condition and limit this design to chronic con-
ditions that require persistent treatment for control. The
duration of withdrawal, selection, noncomparability of pa-
tient groups and reduced numbers of patients completing
the trial may compromise the aims of this study design.
Contrasting the single-blind and double-blind phase
results. Several hypotheses may explain the initial increase
in exercise capacity during amrinone treatment and the lack
of a decrease on withdrawal. The initial comparison eval-
uated each patient as his own control. This should be a
sensitive method for detecting subtle changes and minimiz-
ing variabilities in test results; however, exercise capacity
may also increase on repeat testing as a result of training
effect. The double-blind evaluation was a group compari-
son. Although the randomized groups were comparable with
respect to demography and descriptors of cardiac function,
subtle differences may have been obscured by larger in-
herent variations. Since initial treatment was not double-
blinded, it is possible that investigator bias or hoped for
improvement by patients and medical personnel influenced
the perception of symptoms and encouraged longer exercise
times. Enthusiasm, education in diet, compliance, physical
training and close follow-up evaluation may all contribute
to improved cardiovascular function.
It appears unlikely that initial short-term treatment with
arnrinone altered the congestive heart failure state and af-
fected the long-term response to continued arnrinone treat-
ment. Symptoms and objective test results evaluating car-
diac performance were similar in both groups, suggesting
that the disease process was not greatly ameliorated. The
similarity of amrinone- and placebo-treated groups suggests
that no adverse effects on left ventricular function resulted
from amrinone, a concern that has been raised previously
(2,27,32). No observed change in fluid balance as estimated
by body weight or diuretic needs accompanied continued
amrinone treatment. Since repeat dose titration was not per-
formed, potential tolerance to arnrinone cannot be dis-
counted. It is unclear why the condition of the patients in
this study did not deteriorate after arnrinone withdrawal, as
did that of the patients studied by Maskin et al. (27). In
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their study, a small number of patients in functional class
IV were treated for up to 41 weeks in an open-label fashion
and their condition deteriorated promptly after the discon-
tinuation of amrinone.
Adverse reactions. Adverse reactions to amrinone were
commonly observed in this study and similar to those pre-
viously reported (10,19,28,31,32,41). Side effects gener-
ally limited treatment to daily dosages of 350 mg or less,
which may be one further explanation for the modest initial
drug-related changes and the withdrawal results. The lack
of a parallel placebo-controlled group during the dose titra-
tion phase significantly compromises the evalution of ad-
verse reactions. It is not possible to conclusively identify
or disclaim amrinone as the cause of the observed side
effects, especially sudden death or complex ventricular ar-
rhythmia which are common in patients with severe conges-
tive heart failure. In a previous smaller study (32), the
incidence of spontaneous repetitive ventricular ectopic rhythm
was increased in patients receiving amrinone. It is likely
that the high incidence of gastrointestinal side effects in-
cluding hepatitis is drug-related since these are otherwise
uncommon. In one patient, this diagnosis was confirmed by
biopsy.
Significant differences in the incidence of adverse re-
actions between placebo-treated or arnrinone-continued groups
occurred in the double-blind phase as in the earlier dose
titration phase, though these were generally mild and not
limiting. New or important late side effects in patients tol-
erant of drug for at least 4 weeks were not observed. Throm-
bocytopenia severe enough to prevent continued amrinone
treatment was uncommon in this study. An increase in pe-
ripheral utilization rather than bone marrow suppression
appears to be responsible for the reduction in platelet counts
attributed to amrinone (32,41) . Platelet reduction observed
in this study was not associated with evidence of bleeding.
Objective testing procedures. Echocardiography.
Measurement of echocardiographic indexes, especially the
left ventricular shortening fraction and mean circumferential
fiber shortening, is suggested as a valuable noninvasive
technique for detecting alterations in contractility (42,43) .
In this study, no appreciable change in the echocardio-
graphic measurements occurred despite improvements in
exercise capacity during the initial introduction of amrinone.
This may be a reflection of limitations of the technique in
patients with regional dyssynergy, left bundle branch block ,
variable transducer positioning or the lack of an appreciable
change after amrinone.
Systolic time intervals. The present study failed to dem-
onstrate significant alterations of either the QS2, preejection
period (PEP), left ventricular ejection time (LVET) or
PEPILVET ratio during the initial introduction of amrinone
treatment. The lack of significant changes despite improve-
ment in exercise capacity is unexplained. Inappreciable ef-
fects of amrinone on these indexes or technical problems
may be postulated (44). Previous studies (45) have dem-
onstrated reductions in PEPc, LVETc and QSz during short-
term administration of amrinone.
Exercise testing. Techniques of exercise testing in pa-
tients with congestive heart failure for the purposes of de-
termining functional capacity have not been standardized.
Some investigations (46) have shown that changes in ex-
ercise duration may not correlate with cardiac index or ejec-
tion fraction. Our study utilized a maximal (symptom-lim-
ited) approach that has been criticized for its variability with
respect to the anaerobic threshold (45,46). The relatively
long duration of exercise required to enter the study (8
minutes) may have precluded the selection of patients more
likely to show an increase in exercise capacity in response
to treatment. Though fewer in number, exercise studies
combined with oxygen consumption analyses performed as
part of this study yielded similar results. A previous study
by Weber et aI. (3) reported a sustained increase in maximal
oxygen utilization in patients taking oral amrinone (1.6 mglkg
every 8 hours) for up to 12 weeks. Motivation of patients,
training effects and possible investigator bias may have ac-
counted for the 12% improvement in exercise capacity ob-
served during the single-blind introduction of amrinone,
especially in light of the lack of decline in this value with
withdrawal of active therapy. In an uncontrolled and non-
blinded study, Siskind et aI. (20) observed dramatic im-
provements in the duration of submaximal exercise after the
short-term administration of amrinone. The duration of sub-
maximal exercise was not evaluated in the present study .
Mechanism of action of amrinone. The mechanism of
action for amrinone is unknown and has recently been a
subject of speculation (47,48) . Amrinone does not manifest
its inotropic action through mechanisms similar to those of
cardiac glycosides or beta-adrenergic agonists. Probably acting
to release calcium to the myocardial cell (31,32), amrinone
therapy is not affected by pretreatment with either digitalis,
atropine, reserpine, dibenzyline or beta-adrenergic blocking
agents (2,11-13). Some studies have shown amrinone to
have vasodilator activity (14,18,21,22), which in one in-
vestigation exceeded its effects on contractility (14,19,20);
phosphodiesterase inhibitor activity has also been demon-
strated (33) . It is likely that a combination of inotropic and
vasodilator activity is produced by amrinone, and that im-
provements in left ventricular function result from direct
drug-mediated positive inotropy and reduction in peripheral
vascular resistance and from the indirect withdrawal of aug-
mented sympathetic nerve activity that occurs with im-
proved hemodynamics in the setting of congestive heart
failure .
Addendum
The results of this study and a subsequent (as yet un-
published) placebo-controlled study combined with favor-
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able results from initial trials of a bypyridine analog of
amrinone named Milrinone have prompted the Sterling
Winthrop Research Institute, Rensselaer, New York to stop
the further investigation of oral amrinone for heart failure
(letter January 18, 1984).
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